MAFFinerenone Tablet 10 mg, 20 mg
As an add-on therapy for adults with chronic kidney disease and albuminuria associated with type 2 diabetes:
• who are receiving concomitant optimal standard treatment which includes an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) at maximum tolerated dose in combination with a sodium-glucose co-transporter 2 (SGLT2) inhibitor, unless contraindicated or not tolerated, and
• who have estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73m2 and urine albumin-to-creatinine ratio (UACR) ≥200 mg/g (20 mg/mmol) at the start of treatment.
Finerenone must be initiated by, or in consultation with, a specialist physician experienced in the management of chronic kidney disease and albuminuria associated with type 2 diabetes.
Treatment with finerenone must be discontinued prior to initiating dialysis.